Hajir Al-Jorani

Hajir Al-Jorani

Auto-generated profile, based on publicly available information

Hajir Al-Jorani

Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2023 in Hypertension
Verified
Journal Article
Closed access
HAHajir Al-Jorani
Hajir Al-Jorani
RJRichard Christian Jensen
Richard Christian Jensen
MJMikaela T.E. Jonasson
Mikaela T.E. Jonasson
ABAnna Birukov
Anna Birukov
ASAnne Vibeke Schmedes
Anne Vibeke Schmedes
MAMarianne S. Andersen
Marianne S. Andersen
Background: Synthetic glucocorticoid exposure in late pregnancy may be associated with higher blood pressure in offspring. We hypothesized that endogenous cortisol in pregnancy relates to offspring blood pressure (OBP). Objective: To investigate associations between maternal cortisol status in third trimester pregnancy and OBP. Methods: We included 1317 mother-child pairs from Odense Child Cohort, an observational prospective cohort. Serum (s-) cortisol and 24-hour urine (u-) cortisol and cortisone were assessed in gestational week 28. Offspring systolic blood pressure and diastolic blood pressure were measured at age 3, 18 months, and 3 and 5 years. Associations between maternal cortisol and OBP were examined by mixed effects linear models. Results: All significant associations between maternal cortisol and OBP were negative. In boys in pooled analyses, 1 nmol/L increase in maternal s-cortisol was associated with average decrease in systolic blood pressure (β=−0.003 mmHg [95% CI, −0.005 to −0.0003]) and diastolic blood pressure (β=−0.002 mmHg [95% CI, −0.004 to −0.0004]) after adjusting for confounders. At 3 months of age, higher maternal s-cortisol was significantly associated with lower systolic blood pressure (β=−0.01 mmHg [95% CI, −0.01 to −0.004]) and diastolic blood pressure (β=−0.010 mmHg [95% CI, −0.012 to −0.011]) in boys after adjusting for confounders, which remained significant after adjusting for potential intermediate factors. Conclusions: We found temporal sex dimorphic negative associations between maternal s-cortisol levels and OBP, with significant findings in boys. We conclude that physiological maternal cortisol is not a risk factor for higher blood pressure in offspring up to 5 years of age.

15 July 2025 in Journal of the American Heart Association
Verified
Journal Article
Open access
HAHajir Al‐Jorani
Hajir Al‐Jorani
RJRichard Christian Jensen
Richard Christian Jensen
TJTina K. Jensen
Tina K. Jensen
HChenrik thybo christesen
henrik thybo christesen
JJjan stener jørgensen
jan stener jørgensen
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
Background: Offspring blood pressure (OBP) may be programmed during pregnancy. Accordingly, maternal third‐trimester 24‐hour urine aldosterone levels are associated with fetoplacental trophic effects. Furthermore, high potassium and low sodium intakes are generally recommended in adults with normal renal function. We hypothesized that maternal 24‐hour urine aldosterone levels were positively associated with OBP, and maternal intake of potassium and sodium may influence the association. The study aimed to investigate associations between maternal third‐trimester 24‐hour urine aldosterone, potassium and sodium intake, and OBP. Methods: In the prospective OCC (Odense Child Cohort), 475 mother–child dyads had 24‐hour urine aldosterone from gestational week 29 and OBP (systolic and diastolic), at ages 3 and 18 months and 3 and 5 years. Maternal potassium and sodium intakes were calculated from 24‐hour urine potassium and urine sodium excretions. Results: Increased maternal 24‐hour urine aldosterone associated with higher systolic blood pressure in offspring at ages 3 months (β=0.54 mm Hg [95% CI, 0.29; 0.79]) and 18 months (β=0.24 mm Hg [95% CI, 0.03; 0.44]). One thousand mg/d increase in maternal potassium intake was associated with an average increase in offspring systolic blood pressure of 0.68 mm Hg (95% CI, 0.02–1.34) up to age 5 years (pooled), with significant associations only in girls (β=1.14 mm Hg [95% CI, 0.21–2.08]). No significant association was seen between maternal sodium intake and OBP. Conclusions: Elevated maternal 24‐hour urine aldosterone and higher dietary potassium intake were associated with higher OBP but within normal range in young children, and girls were more susceptible to maternal potassium intake. Registration: URL: https://clinicaltrials.gov . Unique identifier: ID NCT02183558.

4 February 2026 in BMJ Open
Verified
Journal Article
Open access
ADAnja Fenger Dreyer
Anja Fenger Dreyer
SHSimon Bøggild Hansen
Simon Bøggild Hansen
SBStina Willemoes Borresen
Stina Willemoes Borresen
HAHajir Al-Jorani
Hajir Al-Jorani
LBLise Sofie Bislev
Lise Sofie Bislev
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
Introduction: Glucocorticoid therapy is prescribed for a variety of inflammatory conditions and is associated with severe adverse effects. A glucocorticoid withdrawal syndrome (GWS) may occur after prolonged glucocorticoid treatment—with or without biochemical glucocorticoid-induced adrenal insufficiency (GIAI). Previously, GWS was not considered an entity, probably due to the overlap between symptoms of GWS and GIAI. The Addison’s disease-specific quality of life questionnaire (AddiQoL-30) is a validated tool for quantifying symptoms of adrenal insufficiency resembling GWS. In the present study, we test the hypothesis that patients with a low AddiQoL-30 score and/or low cortisol response to a short Synacthen test (SST), after cessation of prednisolone treatment, may benefit from low-dose hydrocortisone therapy without increasing the risk of metabolic and cardiovascular disease during prolonged cortisol exposure. Methods and analysis: REPLACE is a multi-centre, double-blinded, placebo-controlled randomised controlled trial in patients with polymyalgia rheumatica or giant cell arteritis after cessation of prednisolone treatment. Criteria for randomisation are an AddiQoL-30 score ≤85 and/or plasma cortisol response to SST, 30-min p-cortisol >100 and 85; and (2) patients with a SST-stimulated cortisol ≤100 nmol/L. Ethics and dissemination: The study is conducted in accordance with the Declaration of Helsinki, registered at the Clinical Trials Information System (CTIS: 2024-513822-53-00) and Clinicaltrials.gov ( NCT05193396 ), and publications will be in accordance with the recommendations of the International Committee of Medical Journal Editors. The trial is monitored by local independent Good Clinical Practice units and overseen by the Danish Data Protection Agency (journal no. 21/27119), the Regional Committees on Health Research Ethics for Southern Denmark (project ID: S-20210076), the Danish Patient Safety Authority and the Danish Medicines Agency. Trial registration number: NCT05193396 .

24 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
RJRichard Christian Jensen
Richard Christian Jensen
HAHajir Al-Jorani
Hajir Al-Jorani
DGDorte Glintborg
Dorte Glintborg
FNFlemming Nielsen
Flemming Nielsen
BJBoye L. Jensen
Boye L. Jensen
MAMarianne Skovsager Andersen
Marianne Skovsager Andersen
BackgroundPerfluoroalkyl substances (PFAS) are endocrine disrupting chemicals with abilities to interfere with aldosterone synthesis. Aldosterone is an essential steroid hormone and independent determinant of placental weight and birth weight.ObjectiveTo investigate associations of PFAS exposure with 24hour urine and plasma aldosterone in pregnant women.MethodsUsing data from Odense Child Cohort, we investigated associations between serum concentrations of five PFAS - perfluorohexane sulfonic acid (PFHxS), perfluorooctane sulfonic acid (PFOS), perfluorooctanoic acid (PFOA), perfluorononanoic acid (PFNA), and perfluorodecanoic acid (PFDA) - with 24h urine (U-) and plasma (P-) aldosterone during pregnancy using multiple linear regression models.ResultsA doubling in PFOS, PFOA, and PFNA at median gestational week (GW) 12 (25th, 75th percentile: 10, 15) associated with a change in U-aldosterone concentrations at median GW 29 (25th, 75th percentile: 28, 29) by -4.8% (95% CI: -8.4%, -1.0%), -5.9% (95% CI: -9.1%, -2.7%), and -6.2% (95% CI: -9.9%, -2.4%), respectively. Compared to the first tertile, exposure to PFOS and PFOA in third tertile, and PFNA in second and third tertile associated with lower concentrations of U-aldosterone. A dose-response relationship was observed across tertiles for PFOS, PFOA, and PFNA with U-aldosterone. No significant association was demonstrated between PFAS exposure and P-aldosterone at median GW 29 (25th, 75th percentile: 28, 29).ConclusionHigher exposure concentrations of PFOS, PFOA, and PFNA in 1st trimester were associated with lower concentrations of 24h U-aldosterone in 3rd trimester. This inverse association may be a possible mechanistic link adding to PFAS-aldosterone-associated lower placental weight and birth weight.

11 June 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
SBStina Willemoes Borresen
Stina Willemoes Borresen
SHSimon Bøggild Hansen
Simon Bøggild Hansen
HAHajir Al-Jorani
Hajir Al-Jorani
RTRandi Tei
Randi Tei
ADAnja Fenger Dreyer
Anja Fenger Dreyer
MKMarianne Klose
Marianne Klose
Introduction Patients on low-dose prednisolone may develop adrenal insufficiency causing reduced health-related quality of life (HRQoL) and increased risk of adrenal crisis. This study examines whether supplemental hydrocortisone during mild to moderate stress improves HRQoL in patients with polymyalgia rheumatica/giant cell arteritis (PMR/GCA) with adrenal insufficiency on low-dose prednisolone. Methods and analysis A multicentre, randomised, double-blinded, placebo-controlled, clinical trial including patients with PMR/GCA receiving ongoing prednisolone ≤5 mg/day. Eligible patients undergo an adrenocorticotropic hormone (ACTH) test, and 250 patients with a stimulated cortisol<420 nmol/L (biochemical adrenal insufficiency) are randomised 1:1 to supplemental hydrocortisone or placebo during mild to moderate stress (‘sick-days’) for 6 months or until daily prednisolone is stopped. The goal is 200 patients completing ≥3 months intervention period. Patients continue prednisolone tapering according to PMR/GCA guidelines. In the event of severe stress (risk of adrenal crisis), patients receive open-label hydrocortisone treatment. 95 patients with stimulated cortisol ≥420 nmol/L serve as control group. The primary outcome is HRQoL measured as fatigue using ecological momentary assessments (EMA) of the General Fatigue scale from the Multidimensional Fatigue Inventory-20, five times daily in situations of stress (‘sick-days’). EMA will be administered via a smartphone application ‘EMA live’. Differences in mean fatigue scores during sick-days between hydrocortisone and placebo will be analysed using mixed models for repeated measures. Secondary outcomes include daily smartphone-based symptom reporting, additional HRQoL questionnaires, adrenal crises, adverse effects from glucocorticoid excess, serial ACTH tests and biomarkers of adrenal insufficiency. Ethics and dissemination The study is approved by the Ethics Committee of the Capital Region of Denmark and the Danish Medicines Agency. Recruitment began June 2022. The last patient’s last visit is expected in 2026. Results will be disseminated via peer-reviewed publication and conference presentations. Trial registration numbers EudraCT:2021-002528-18, CTIS:2024-518272-30-00, NCT05435781.